Clinical trials: Neoplasms, Thyroid
Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells (donor natural killer [NK] cells) and how well they work when given together with cyclophosphamide and…
- Conditions
- Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma, Recurrent Malignant Endocrine Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm
- Trial name
- NCT03420963
- Testing
- Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cyclophosphamide, Etoposide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Carcinoma, Hypopharyngeal Carcinoma
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
This randomized pilot clinical trial studies the effects of taking doxepin hydrochloride as compared to placebo (inactive drug) in treating esophageal pain in patients with cancer located in the chest area receiving radiation…
- Conditions
- Esophageal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Lymphoma
- Trial name
- NCT02062632
- Testing
- Doxepin Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Thyroid, Thyroid Nodule
Comparison of TOETVA and Conventional Thyroidectomy
Introduction-Objective: The application of transoral endoscopic thyroidectomy vestibular approach (TOETVA) is gradually increasing recently.
- Conditions
- Thyroid, Thyroid Nodule, Surgery
- Trial name
- TOETVA (NCT04647006)
- Testing
- thyroid
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- MUnlu
Cancer of Thyroid, Vertebral Fracture
Study of the Prevalence of Osteo-metabolic Complications in Patients With Thyroid Cancer
This is a multicenter retrospective observational study aimed to evaluate the prevalence of osteo-metabolic complications in patients with thyroid cancer.
- Conditions
- Cancer of Thyroid, Vertebral Fracture, Osteoporosis
- Trial name
- NCT06627998
- Testing
- Diagnostic (chest x-ray /DXA)and clinical data collected for clinical practice
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- IRCCS San Raffaele
Thyroid Cancer
Dental Safety Profile of High-Dose Radioiodine Therapy
We aim to assess the incidence of oral and dental adverse events after high-dose radioiodine therapy for differentiated thyroid cancer.
- Trial name
- NCT00439478
- Testing
- Radioiodine
- Where
- Switzerland
- Volunteers
- 202 people
- Sponsor
- University Hospital, Basel, Switzerland
Thyroid Nodule
Myo-inositol and Selenium in Indeterminate Thyroid Nodules (TIR3a)
Thyroid nodules present a variable risk of malignancy depending on the cytological result obtained from the ultrasound-assisted thyroid fine needle aspiration biopsy.
- Trial name
- MYOSEL (NCT06736015)
- Testing
- Myo-Inositol 600 mg + Selenium 83 mcg
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Regina Elena Cancer Institute
Neoplasms, Colorectal Neoplasms
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.
- Conditions
- Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms
- Trial name
- ALpha-T (NCT04644315)
- Testing
- Alectinib
- Where
- 29 sites in United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Papillary Thyroid Microcarcinoma, Thyroid Cancer
Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma
This is a single center prospective clinical trial with regard to efficacy and safety of radiofrequency ablation of papillary thyroid microcarcinoma.
- Trial name
- RFAforPTMC (NCT03432299)
- Testing
- RFA for PTMC
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Anaplastic Thyroid Cancer
Review of Multimodality Management of Anaplastic Thyroid Cancer
To describe the outcome of patients with anaplastic thyroid cancer treated with hyperfractionated radiotherapy and concomitant chemotherapy
- Trial name
- NCT00280852
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Alberta Health services
Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
This phase II trial studies how well 177Lu-DOTATATE works in treating patients with rare endocrine cancers that have spread from where they started to nearby tissue or lymph nodes (locally advanced), spread to other places in the…
- Conditions
- Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma
- Trial name
- NCT04106843
- Testing
- Lutetium Lu 177 Dotatate
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Thyroid Cancer, Thyroid
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is a registry study.
- Conditions
- Thyroid Cancer, Thyroid, Refractory Thyroid Cancer
- Trial name
- NCT05733013
- Testing
- Surveillance Visit
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thyroid Neoplasms
Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients
Papillary cancer may affect patients of any age,with a good prognosis. Most of young patients may hence procreate as often as the general population.131iodine is an essential tool during treatment of thyroid cancer.
- Trial name
- SAPIRA (NCT01150318)
- Testing
- Administration of 131 iodine
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Renal Cell Carcinoma, Hepatocellular Carcinoma
Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
The objective of this Post Marketing Surveillance (PMS) is to collect and describe safety and effectiveness profile of Cabometyx™ in real clinical practice setting, according to the approved labelling after the approval of…
- Conditions
- Renal Cell Carcinoma, Hepatocellular Carcinoma, Differentiated Thyroid Carcinoma
- Trial name
- NCT03776123
- Where
- 47 sites in South Korea
- Volunteers
- 347 people
- Sponsor
- Ipsen
Heart Diseases, CKD
Nurse-led Medication Self-management Intervention in the Improvement of Medication Adherence
Back ground \& Aims Adult patients suffering from multimorbidity are at high risk of medication non-adherence. It has been well established that self-management support is an effective strategy to enhance medication adherence for…
- Conditions
- Heart Diseases, CKD, Diabetes, Cancer
- Trial name
- NCT05645653
- Testing
- Motivational tteaching
- Volunteers
- 100 people
- Sponsor
- Hamad Medical Corporation
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Thyroid Cancer
Association Between Cancer Cells and Normal Versus (Vs.) Low Levels of Thyroid Hormones in the Serum
Much experimental data has suggested that thyroid hormones (T3 and T4) may modulate neoplastic cells and that T3/T4 deprivation may remove this stimulus.
- Trial name
- NCT01153945
- Where
- Israel
- Sponsor
- Meir Medical Center
Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation, Advanced PDTC or ATC With NRAS Mutation
Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
This phase II trial evaluates Tunlametinib (MEK inhibitor) ± PD-1 in NRAS-mutant advanced thyroid cancer. Key Objectives: Assess efficacy (ORR by RECIST v1.1) Evaluate safety profiles Study Design: Single-arm, single-center 4…
- Trial name
- NCT06970353
- Testing
- Tunlametinib, Tunlametinib+PD-1 mAb
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Thyroid Carcinoma
Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma
This study is to evaluate the effectiveness of nsPFA in treating papillary thyroid microcarcinoma. T
- Trial name
- NCT07218315
- Testing
- CellFX nsPFA Percutaneous Electrode System
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Thyroid Cancer, Papillary Thyroid Carcinoma
Active Surveillance for Low-risk Papillary Thyroid Carcinoma
This is a multi-center, non-randomized, prospective observational cohort study aimed at establishing a cohort of low-risk papillary thyroid cancer patients with a maximum tumor diameter of 1.5 cm or less, consisting of an active…
- Trial name
- MAeSTro-EXP (NCT06261190)
- Where
- 4 sites in South Korea
- Volunteers
- 499 people
- Sponsor
- National Cancer Center, Korea
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.